Moyamoya Disease in a Young Female With Neurofibromatosis Type 1

Yusuf Mehkri 1, Lorena Figueredo Rivas 2, Rebecca Jules 2, Ibrahim S. Tuna 3, Brian L Hoh 1, Hans H. Shuhaiber 2

1. Department of Neurosurgery, University of Florida College of Medicine, Gainesville, USA 2. Department of Neurology, University of Florida College of Medicine, Gainesville, USA 3. Department of Radiology, University of Florida College of Medicine, Gainesville, USA

Corresponding author: Yusuf Mehkri, yamehkri@gmail.com

Abstract

Moyamoya disease (MMD) is a rare cerebrovascular disease characterized by progressive stenosis of the terminal portions of the internal carotid arteries (ICAs) and the development of a network of abnormal collateral vessels. This case depicts a 25-year-old African American female patient with neurofibromatosis type 1 (NF-1), whose initial hospital presentation occurred in a hypertensive emergency setting. Surveillance studies with magnetic resonance imaging (MRI) revealed multiple asymptomatic right cortical strokes. Genetic testing evidenced a novel, unique pathogenic variant on the NF-1 gene.

The patient underwent combined bypass surgery first and then was placed on aspirin and a blood pressure control regimen. Our case illustrates the need for clinicians to include moyamoya disease in the list of differential diagnoses when encountering a young patient, without major risk factors, presenting with ischemic stroke. It should be considered even with no known history of previously diagnosed MMD or NF-1, as these pathologies may have yet to be evaluated in subclinical cases.

Introduction

Moyamoya disease (MMD), a rare cerebrovascular disease characterized by progressive stenosis of the internal carotid arteries (ICAs) and the development of abnormal collateral vessels, was first described in 1957 in Japan and is thought to have a predilection for people of Asian descent [1,2]. The highest rates of MDD were found in Japan with a prevalence of 3.16-10.5/100,000 and an incidence of 0.35-1.13/100,000/year [1,2]. On the other hand, it is a fairly rare occurrence in the African American community, with a reported incidence of 0.13/100,000 [3]. Nonetheless, MMD is globally recognized as one of the major causes of childhood stroke.

Age of onset of MMD follows a bimodal distribution, with first onset between five and 10 years and second onset between 30 and 50 years [4]. When MMD is associated with an underlying condition such as neurofibromatosis type 1 (NF-1), it is referred to as moyamoya syndrome (MMS) [5]. Regardless of the cause, moyamoya angiopathy increases the risk of ischemic and hemorrhagic events. The specific treatment to prevent such complications is usually revascularization surgery in conjunction with therapeutics relating to the underlying disease. The exact pathophysiology of moyamoya is unknown. However, genetic factors appear to play a major role in this disorder. We present a case highlighting the clinical presentation and treatment plan for a patient with a novel NF-1 mutation who was later diagnosed with MMS.

Case Presentation

A 25-year-old patient with a history of hypertension and NF-1 presented with hypertensive emergency, complaining of severe headache in the setting of an unremarkable neurological examination. Computed tomography angiography (CTA) showed bilateral ICA stenosis and near occlusion of the superior division of the right M2 segment, resulting in complex collaterals and anastomotic supplies (Figure 1). Contribution from the posterior circulation via leptomeningeal collaterals was also evident. These findings were indicative of MMD; however, extracranial-intracranial (EC-IC) bypass was initially deferred due to a lack of neurovascular ischemic symptoms and the presence of auto bypass. She was instead placed on aggressive blood pressure control.

How to cite this article

Mehkri Y, Rivas L, Jules R, et al. (October 29, 2021) Moyamoya Disease in a Young Female With Neurofibromatosis Type 1. Cureus 13(10): e19121. DOI 10.7759/cureus.19121
Four years later, the patient was referred to our institution for surgical evaluation given multiple, asymptomatic right cortical strokes evident on surveillance studies. Digital subtraction angiography study showed worsening MMD (right worse than left), and a small left P2-P3 aneurysm. A direct and indirect EC-IC bypass was performed, along with an encephaloduroarteriosynangiosis (EDAS). The right frontal superficial temporal branch was used for anastomosis to the M4 division of her right middle cerebral artery (MCA). The parietal branch was used for EDAS. The patient is currently at two months post-op on prophylactic aspirin and lisinopril. Genetic studies revealed a novel, unique pathogenic variant, c.1143_1144del (p.Ser382Leufs*13), found to be a premature translational stop signal in the exon 10 of the NF-1 gene that has not been previously reported in individuals with NF-1 related conditions.

Of note, the patient’s mother had a history of neurofibromas due to NF-1 and essential hypertension following her last pregnancy. She passed away from a large left basal ganglia hemorrhage with intraventricular extension secondary to her malignant hypertension and complicated by cerebral edema and significant herniation.

**Discussion**

MMD is typically characterized by progressive stenosis of the ICA terminals and/or the anterior and middle cerebral arteries bilaterally [6]. Rarely, the posterior circulation and the basilar artery may be involved, which was something appreciated in our young adult patient with NF-1 and MMS [7]. Reduced blood flow to the main arteries of the brain leads to the development of extensive collateral vessels that are small and irregular called "moyamoya vessels" [8]. This was also evident in our patient’s CT angiography, shown as the characteristic "puff of smoke" associated with the pathology (Figure 2).
Despite the unclear pathophysiology responsible for the vasculopathies behind MMD, associations with loci on chromosomes 3, 6, 8, and 17, as well as specific human leukocyte antigen haplotypes, have been described [9,10]. A 2008 study reported a major gene locus for autosomal dominant MMD on chromosome 17q25 [11]. The c.14576G>A variant in ring finger protein 213 (RNF213) was recently identified as a susceptibility gene variant for MMD [12-14]. The role of NF-1 in the occurrence of MMD is controversial; however, the close proximity of the NF-1 gene (17q11.2) to the familial moyamoya gene (17q25), could potentially justify the relationship between these two pathologies [15]. Genetic studies in our patient revealed a novel, unique pathogenic variant, c.1143_1144del (p.Ser382Leufs*13), found to be a premature translational stop signal in the exon 10 of the NF-1 gene that has yet to join the literature regarding individuals with NF-1 related conditions. This syndrome has been extensively described throughout the years as a result of a loss of function mutation of the neurofibromin gene, which appears to differ from our findings [15].

The clinical symptoms in MMD differ between children and adults. Adults present with transient or permanent cerebral infarction and intracranial hemorrhage, whereas children present mainly with ischemic events [1,16]. This is likely due to tearing of the moyamoya vessels as a result of the higher blood pressures typically seen in adults with MMD [1]. Our patient presented with multiple ischemic events secondary to MMD, and her diagnosis occurred at the age of 21 years.

The gold standard diagnosis for MMD is cerebral conventional angiography with ICAes, external carotid arteries, and vertebral arteries injection. It allows for the visualization of both the stenotic vessels and detailed mapping of collateral networks which is essential for treatment planning. Medical management in the form of antplatelet therapy is indicated in all patients with MMD who have suffered from ischemic events [17]. Aspirin is often used at 50-100 mg daily in children [18]. Antplatelet therapy may be used alone if the revascularization therapy is delayed due to recent ischemic events, infection, or if the patient is clinically asymptomatic with no evidence of markedly impaired cerebral perfusion [18]. On initial presentation, our patient had adequate spontaneous revascularization and surgery was therefore deferred.

Surgical management is the mainstay of treatment in MMD. In symptomatic patients with MMD, bypass surgery is more effective than conservative treatment to prevent future strokes. Direct bypass seems to reduce risk of future stroke more than indirect bypass. The combined approach also been associated with better outcomes than the indirect bypass [5,19]. Our patient underwent combined bypass surgery first and then was placed on aspirin. A retrospective study showed that this postoperative aspirin therapy might improve outcome based on the modified Rankin scale measurement without increasing risk of intracranial hemorrhage. However, it also found that postoperative aspirin administration did not reduce the incidence of bypass graft occlusion or the incidence of postoperative ischemic stroke [20]. More studies are needed to provide evidence for postoperative antplatelet therapy in MMD management, especially when combined with different surgical approaches.

Conclusions

In conclusion, we recommend that clinicians include MMD to the list of differential diagnoses when encountering a young patient presenting with ischemic stroke. It should be considered even with no known history of previously diagnosed MMD or NF-1, as these pathologies may have yet to be evaluated in subclinical cases. The management of MMD and MMS depends primarily on symptomaticity. Asymptomatic
disease may be managed with aspirin with possible revascularization in the future, whereas symptomatic disease requires immediate surgical revascularization.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Guery S, Tournier-Lasserve E, Hervé D, Kosssorotoff M: Moyamoya disease and syndromes: from genetics to clinical management. Appl Clin Genet. 2015, 8:49-68. 10.2147/TACG.S42772
2. Wakai K, Tamakoshi A, Ikizaki K, et al.: Epidemiological features of moyamoya disease in Japan: findings from a nationwide survey. Clin Neurol Neurosurg. 1997, 99:1-5. 10.1016/a0305-8460(97)00051-0
3. Li Q, Gao Y, Xin W, et al.: Meta-analysis of prognosis of different treatments for symptomatic moyamoya disease. World Neurosurg. 2019, 127:354-61. 10.1016/j.wneu.2019.04.062
4. Fukui M, Kono S, Suetsuki K, Ikizaki K: Moyamoya disease. Neuropathology, 2000, 20:61-4. 10.1046/j.1440-1789.2000.00500.x
5. Suzuki T, Koizumi J, Uchida K, Shiraiishi H, Hori M: Carcnoform-induced organic mental disorders. Jpn J Psychiatry Neurol. 1990, 44:723-7. 10.1111/j.1440-1819.1990.tb01650.x
6. Serafini NB, Serafini CB, Vinhas AS, Godinho MB: Moyamoya syndrome associated with neurofibromatosis type I in a pediatric patient. An Bras Dermatol. 2017, 92:870-3. 10.1590/abd1806-4841.20176829
7. Azzam DB, Sharma AN, Tournier E, Chan AY: A case report of moyamoya disease presenting as headache in a 35-year-old Hispanic man. Cureus. 2019, 11:10.7759/cureus.4426
8. Scott RM, Smith ER: Moyamoya disease and moyamoya syndrome. N Engl J Med. 2009, 360:1226-37. 10.1056/NEJMra0804622
9. Ikeda H, Sasaki T, Yoshimoto T, Fukui M, Arinami T: Mapping of a familial moyamoya disease gene to chromosome 3p24.2-p26. Am J Hum Genet. 1999, 64:533-7. 10.1086/302245
10. Nanba R, Tada M, Kuroda S, Houkin K, Iwasaki Y: Sequence analysis and bioinformatics analysis of chromosome 17q25 in familial moyamoya disease. Childs Nerv Syst. 2005, 21:62-8. 10.1007/s00381-004-1005-4
11. Inoue TK, Ikizaki K, Sasazuki T, Matsushima T, Fukui M: Linkage analysis of moyamoya disease on chromosome 6. J Child Neurol. 2000, 15:179-82. 10.1177/088307380001500507
12. Han H, Pyo CW, Yoo DS, Huh PW, Cho KS, Kim DS: Associations of Moyamoya patients with HLA class I and class II alleles in the Korean population. J Korean Med Sci. 2005, 18:876-80. 10.5334/kjms.2005.18.6.876
13. Sakurai K, Horiuchi Y, Ikeda H, Ikizaki K, Yoshimoto T, Fukui M, Arinami T: A novel susceptibility locus for moyamoya disease on chromosome 3q23. J Hum Genet. 2004, 49:278-81. 10.1007/s10038-004-0145-6
14. Kamada F, Aoki Y, Narisawa A, et al.: A genome-wide association study identifies RNF213 as the first moyamoya disease gene. J Hum Genet. 2011, 56:53-40. 10.1038/jhg.2010.132
15. Rad E, Tee AR: Neurofibromatosis type I: fundamental insights into cell signalling and cancer. Semin Cell Dev Biol. 2016, 52:59-46. 10.1016/j.semcdb.2016.02.007
16. Chiu D, Shedd P, Bratina P, Grotta JC: Clinical features of moyamoya disease in the United States. Stroke. 1998, 29:1347-51. 10.1161/01.str.29.7.1347
17. Onozuka D, Hagihara A, Nishimura K, et al.: Prehospital antiplatelet use and functional status on admission of patients with non-va姆orrhagic moyamoya disease: a nationwide retrospective cohort study (J-ASPECT study). BMJ Open. 2016, 6:1-8. 10.1136/bmjopen-2015-009942
18. Smith ER, Scott RM: Spontaneous occlusion of the circle of Willis in children: pediatric moyamoya summary with proposed evidence-based practice guidelines. A review. J Neurosurg Pediatr. 2012, 9:353-60. 10.3171/2011.12.PEDS1172
19. Yao Z, You C: Effect of surgery on the long-term functional outcome of moyamoya disease: a meta-analysis. Turk Neurosurg. 2019, 29:171-9. 10.5157/1019-5149.TN.22598-18.3
20. Zhao Y, Zhang Q, Zhang D, Zhao Y: Effect of aspirin in postoperative management of adult ischemic moyamoya disease. World Neurosurg. 2017, 105:728-31. 10.1016/j.wneu.2017.06.057